What is she best known for?
The fields of study she is best known for:
Anna Orlova focuses on Affibody molecule, Biodistribution, Cancer research, Molecular imaging and Pathology.
Her research in Affibody molecule intersects with topics in Molecular biology, Biophysics and Cysteine.
Anna Orlova combines subjects such as Immunology, Oligopeptide, Peptide, Peptide synthesis and Histidine with her study of Biodistribution.
Her Cancer research research is multidisciplinary, incorporating elements of Preclinical imaging, Trastuzumab, Tyrosine kinase, Tumour targeting and Antibody.
Her Molecular imaging research focuses on Epidermal growth factor receptor and how it relates to Dimer and A431 cells.
Her Pathology research is multidisciplinary, relying on both Pet imaging, Positron emission tomography, Receptor and Breast cancer.
Her most cited work include:
- Tumor imaging using a picomolar affinity HER2 binding affibody molecule. (414 citations)
- Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules (222 citations)
- Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule (188 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of investigation include Biodistribution, Cancer research, Affibody molecule, Molecular imaging and In vitro.
Her work in Biodistribution tackles topics such as Biophysics which are related to areas like Molecule and Stereochemistry.
Her work carried out in the field of Cancer research brings together such families of science as Cancer, Prostate cancer, Pathology, Receptor and Monoclonal antibody.
Anna Orlova has researched Affibody molecule in several fields, including Preclinical imaging, Epidermal growth factor receptor, Nuclear medicine, DOTA and Combinatorial chemistry.
The various areas that Anna Orlova examines in her Molecular imaging study include Scaffold protein, Molecular targets, Positron emission tomography, Breast cancer and DARPin.
Her research integrates issues of Molecular biology and Radionuclide therapy in her study of In vitro.
She most often published in these fields:
- Biodistribution (56.97%)
- Cancer research (48.92%)
- Affibody molecule (41.18%)
What were the highlights of her more recent work (between 2018-2021)?
- Biodistribution (56.97%)
- Molecular imaging (38.39%)
- Cancer research (48.92%)
In recent papers she was focusing on the following fields of study:
Her scientific interests lie mostly in Biodistribution, Molecular imaging, Cancer research, In vitro and Biophysics.
Her study in Biodistribution focuses on Affibody molecule in particular.
Her studies in Affibody molecule integrate themes in fields like Cancer cell and Cytotoxic T cell.
As a member of one scientific family, she mostly works in the field of Molecular imaging, focusing on Scaffold protein and, on occasion, Spect imaging and Cancer.
Her Cancer research research is multidisciplinary, incorporating perspectives in Molecular medicine, Targeted therapy, DARPin, Prostate cancer and Monoclonal antibody.
Her studies deal with areas such as Chelation, Her2 expression, Denaturation and Circular dichroism as well as Biophysics.
Between 2018 and 2021, her most popular works were:
- Affibody Molecules as Targeting Vectors for PET Imaging (15 citations)
- Affibody Molecules as Targeting Vectors for PET Imaging (15 citations)
- Affibody Molecules as Targeting Vectors for PET Imaging (15 citations)
In her most recent research, the most cited papers focused on:
Her main research concerns Biodistribution, Molecular imaging, Biophysics, Scaffold protein and Cancer research.
Her Biodistribution research is under the purview of In vitro.
Her work deals with themes such as Molecule, Breast cancer, DARPin and Binding selectivity, which intersect with Molecular imaging.
Anna Orlova has included themes like Chelation, Cancer and Affibody molecule in her Biophysics study.
Her biological study spans a wide range of topics, including Trimer, DOTA, Endogeny, Glutaric acid and Receptor expression.
Anna Orlova works mostly in the field of Cancer research, limiting it down to concerns involving Prostate cancer and, occasionally, Receptor, Radionuclide therapy, Antagonist, Peptide and Trastuzumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
